So far, there is no pharmaceutical option to reduce the extremely high synthesis/level of CRP during an acute phase response, but the rapid reduction of high CRP levels in medium and severe courses of COVID-19 was proposed early on during the pandemic (21–23) and also recently (14, 24). This evidence concerns the gene CRP and COVID-19.